CBPP mortality rates can reach up to 50% in affected herds.
The partnership will see Biovet lead safety, efficacy, and field trials, as well as the process toward market authorisation, while GALVmed supports downstream development and deployment.
MEVAC® IB VAR 2 demonstrates how targeted vaccination strategies, coupled with sound management, can support both performance and resilience.
While the resumption of local vaccine manufacturing marks a turning point, South Africa’s production capacity will initially remain limited.
The ten-year agreement provides for the creation of a bank containing 10 million doses of antigens from the two foot-and-mouth disease virus serotypes most prevalent in Brazil.
Since 2021, highly pathogenic avian influenza H5 has caused unprecedented losses worldwide.
For more than a decade, OBP has struggled with outdated infrastructure, mismanagement, and leadership instability.
Meanwhile, the European Commission recently approved Merck’s NOBILIS MULTRIVA™ REOm vaccine for chickens, designed to protect avian reovirus (ARV) genotypes 1 and 4.
Its mission is to accelerate vaccine innovation for diseases often overlooked by mainstream pharmaceutical companies.